Kidney Disease

New Indication: Invokana

Invokana is now approved to reduce the risk of end-stage renal disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria >300mg/day.

RNAi Therapy Gets Breakthrough Status for Primary Hyperoxaluria Type 1

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to DCR-PHXC (Dicerna Pharmaceuticals) for the treatment of patients with primary hyperoxaluria type 1 (caused by a mutation in the AGXT gene). DCR-PHXC is a ribonucleic acid interference (RNAi) investigational treatment that works by inhibiting the lactate dehydrogenase A enzyme (LDHA) in the liver…